https://orcid.org/0000-0002-9419-2415
Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Nan Su, Lili Zhi, Fengxia Liu, Yongsheng Wang, Qingling Zhang, Xiansheng Liu, Xueyan Wang, Guodong Hao, Xiuqin Zhang, Qiang Hu, Monica Ligueros-Saylan, Alkaz Uddin, Jing Yang, Tiantian Liang, Liju Ding, Runqin Li & Chen Wang. (2023) Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study. Journal of Asthma and Allergy 16, pages 625-636.
Read now
Read now
Andriana I Papaioannou, Evangelia Fouka, Konstantinos Bartziokas, Maria Kallieri, Angelos Vontetsianos, Konstantinos Porpodis, Nikoletta Rovina, Stelios Loukides & Petros Bakakos. (2023) Defining response to therapy with biologics in severe asthma: from global evaluation to super response and remission. Expert Review of Respiratory Medicine 17:6, pages 481-493.
Read now
Read now
Manuel Enrique Machado-Duque, Andrés Gaviria-Mendoza, Luis Fernando Valladales-Restrepo, Carmen García-Nuncira, María Laucho-Contreras & Jorge E Machado-Alba. (2022) Utilization Patterns and Trends in the Use of Medications for Asthma in a Cohort of Colombian Patients. Journal of Asthma and Allergy 15, pages 1347-1357.
Read now
Read now
Articles from other publishers (6)
V. V. Naumova, Е. К. Beltyukov, V. Ch. Abdullaev, A. U. Petukhova, A. A. Shtanova & D. A. Stepina. (2023) Efficacy of two-year anti-IgE therapy in patients with severe allergic bronchial asthma in Sverdlovsk region. Meditsinskiy sovet = Medical Council:4, pages 8-17.
Crossref
Crossref
Na Li, Linfeng Cao, Ming Zhang, Chunyuan Fei & Jingjing Deng. (2022) Response to Omalizumab as an Add-On Therapy in the Treatment of Allergic Asthma in Adult Chinese Patients—A Retrospective Study. Vaccines 10:12, pages 2068.
Crossref
Crossref
Carlos A. Torres-Duque, Jaime Ocampo-Gómez, Mauricio Morales Castillo, Diana Cano-Rosales, Ángela Giraldo-Montoya, Freddy Rodríguez, Isabel Palacios-Ortega, Mauricio Durán-Silva, Humberto Reynales, Elizabeth García, Juliana Proaños-Jurado, Alejandro Carreño, Ana M. Celis, Edgardo Chapman, Maria B. García, Mauricio González-García, Libardo Jiménez-Maldonado, Julian Londoño, Edison Morales, Mauricio Morales-Castillo, Viviana Valencia, Ingrid Vanegas & Leslie Vargas-Ramírez. (2022) Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia. BMC Pulmonary Medicine 22:1.
Crossref
Crossref
Francois Nantel, Juejing Ling, Meagan Rachich, Odalis Asin-Milan, Brad Millson, Shane Golden, Huijuan Yang, Purva Barot & Allen J. Lehman. (2022) Usage and Adherence of Seven Advanced Therapies with Differing Mechanisms of Action for Inflammatory Arthritis in Canada. Rheumatology and Therapy 9:5, pages 1399-1420.
Crossref
Crossref
Delbert R. Dorscheid, Jason K. Lee, Warren Ramesh, Mark Greenwald & Jaime Del Carpio. (2022) Guidance for Administering Biologics for Severe Asthma and Allergic Conditions. Canadian Respiratory Journal 2022, pages 1-9.
Crossref
Crossref
Stephen G. Noorduyn, Karissa Johnston, Kathy Osenenko, Niroshan Sriskandarajah, Alain Gendron & Lawrence Mbuagbaw. (2021) Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma. ERJ Open Research 7:4, pages 00465-2021.
Crossref
Crossref